64. 以 Glucocorticoids 來治療酒精性肝炎之敘述何者為正確？
(1) Glucocorticoids 可用於不同嚴重程度之酒精性肝炎
(2) 有消化道出血或活動性感染時，避免使用
(3) 因酒精性肝炎所導致之 hepatorenal syndrome 並無顯著療效
(4) 對 discriminant function ＞ 32 者較有助益
(5) 對 spontaneous hepatic encephalopathy 者較有助益
(A) (1)＋(3)＋(4)
(B) (2)＋(3)＋(4)
(C) (2)＋(4)＋(5)
(D) (2)＋(4)

(E) (2)＋(3)＋(4)＋(5)

60. 關於慢性 B 型肝炎治療抗藥性(resistance)的敘述何者為是？ (A) 生化突破(Biochemical breakthrough)會出現在病毒突破(virological breakthrough)之前 (B) 對於 lamivudine 抗藥性最好的治療方式是給予 entecavir 1mg QD (C) Roadmap 關念有助於增加抗藥性的出現 (D) 對於 lamivudine 抗藥性最好的治療方式是改以 add on adefovir 10mg QD (E) 以上皆非

61. 一位癌症患者欲接受化學藥物治療前，其抽血的 HBsAg(-), Anti-HBc(+) and HBV DNA undetectable，請問下列何種藥物最有可能引起 B 肝發作？(A) 低劑量類固醇(B) cyclophosphamide(C) vincristine(D) R-CHOP(E) 以上皆是

62. 下列之臨床狀況，何者可與酒精性肝病相似？(1) Non-alcoholic fatty liver disease(2) Hereditary hemochromatosis(3) Amiodarone hepatotoxicity(4) Budd-Chiari syndrome(A) (1)＋(2)(B) (1)＋(3)(C) (1)＋(3)＋(4)(D) (1)＋(2)＋(3)(E) (1)＋(2)＋(3)＋(4)

63. 有關肝臟內各細胞之敘述，何者為是？(1) 肝臟內各細胞中之 parenchyma cells 包括 hepatocytes 及 sinusoidalendothelial cells(2) stellate cells 位於 space of Disse 中(3) hepatocytes 之大小約在 20 至 30 μm 間(4) hepatocytes 約佔成人肝臟各細胞的 60%(A) (1)＋(2)(B) (1)＋(2)＋(3)(C) (2)＋(3)＋(4)(D) (1)＋(3)＋(4)(E) (1)＋(2)＋(3)＋(4)

65. 目前使用口服抗 B 型肝炎藥物，若要考慮停藥，除了 e 抗原陰轉外，以下何者是 現階段停藥的最佳 Biomarker？ (A) HBsAg 定量＞ 100 IU/mL (B) HBsAg 定量＜ 100 IU/mL (C) HBV DNA ＜ 2000 IU/mL (D) HBcrAg ＜ 4 log (E) HBcrAg ＜ 3 Log

66. HCC systemic therapy，依據 phase 3 clinical trials 的結果，其 overall survival相對於 sorafenib 的 HR(hazard ratio)，由小至大排列順序，何者正確？(1) IMbrave 150, Atezolizumab + Bevacizumab(2) HIMALAYA, STRIDE: Tremelimumab + Durvalumab(3) COSMIC-312, Cabozantinib + Atezolizumab(4) CARES-310, Camrelizumab + Rivoceranib(A) (1)—(2)—(4)—(3)(B) (1)—(4)—(2)—(3)(C) (2)—(1)—(3)—(4)(D) (4)—(2)—(1)—(3)(E) (4)—(1)—(2)—(3)

67. 關於中期肝癌 TACE unsuitable 的範圍，2020 APPLE Expert Consensus Statement 與 2023 AASLD Practice Guidance 比較，其中包括下列何種共同項目？(1) ＞ 50% liver involvement(2) Infiltrative type(3) Bilobar extensive HCC(4) Extranodular growth type HCC(5) Poorly differentiated HCC(A) (2)＋(3)(B) (1)＋(2)＋(3)(C) (2)＋(3)＋(4)＋(5)(D) (2)＋(3)＋(5)(E) (1)＋(2)＋(3)＋(4)＋(5)

68. 依據 2023 AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma，下列何者敘述正確？(1) AASLD advises against the combination of systemic therapy withtransarterial therapies for BCLC Stage B HCC outside of a clinical trial setting(2) Patients with BCLC Stage B HCC should be treated with transarterialchemoembolization(3) AASLD advises radioembolization as an alternative therapy tochemoembolization in patients with BCLC Stage B HCC(4) Patients with Child-Turcotte-Pugh class C cirrhosis should be enrolled insurveillance programs(A) (3)＋(4)(B) (1)＋(2)(C) (3)(D) (1)＋(2)＋(3)(E) (1)＋(2)＋(3)＋(4)

69. 依據 2023 AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma，下列何者敘述正確？(1) AASLD does not advise use of statins, aspirin, and metformin solely toreduce HCC risk(2) AASLD recommends against routine use of HCC surveillance in patientswith NAFLD who have advanced fibrosis but without cirrhosis(3) AASLD advises repeat short-interval ultrasound and AFP in approximately3-6 months for patients with a ＜1 cm lesion on abdominal ultrasound(4) In patients with an LI-RADS-4 observation, AASLD advises repeatcross-sectional imaging in 3–6 months(A) (3)＋(4)(B) (1)＋(2)(C) (3)(D) (1)＋(2)＋(3)(E) (1)＋(2)＋(3)＋(4)

70. 依據 2023 AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma，下列何者敘述正確？(1) Patients with HCC beyond BCLC Stage 0 should undergo non-contrast CTof the chest to evaluate for metastatic disease(2) AASLD advises use of the BCLC system(3) Routine postoperative surveillance should be performed to detectrecurrence using contrast-enhanced multiphasic CT or MRI every 3–6months for all patients with HCC following liver resection(4) AASLD recommends against routine use of HCC surveillance in patientswith HCV infection post-SVR with advanced fibrosis but without cirrhosis(A) (3)＋(4)(B) (1)＋(2)(C) (3)(D) (1)＋(2)＋(3)(E) (1)＋(2)＋(3)＋(4)